CEO Dan Hicklin (Werewolf)
January 7, 2021 07:00 AM ESTUpdated 11:34 AM
Financing

Were­wolf pre­pares to bare its teeth in 1st tri­al for tar­get­ed cy­tokine tu­mor fight­ers with new round of in­vestor cash

Conner Mitchell

Boston area biotech Were­wolf Ther­a­peu­tics launched in late 2019 with the goal of chas­ing nov­el im­mune sys­tem mod­u­la­tors to erad­i­cate sol­id tu­mors. Just over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times